Avedro Announces $25 Million in Funding to Fuel Innovation and Commercial GrowthHongbo Lu, PhD, Joins Avedro Board of Directors WALTHAM, Mass., May 2, 2018-- Avedro, Inc., an ophthalmic pharmaceutical and medical device company and the world leader in corneal remodeling, today announced that it has secured $25 million in financing led by Lilly Asia Ventures (LAV) with major participation from existing investors OrbiMed Advisors, InterWest Partners and HealthQuest Capital. Avedro will leverage this funding to invest in product development, clinical studies and commercial efforts, including expansion of sales and reimbursement support.